Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02354664
Other study ID # IRB201400763
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 2015
Est. completion date October 19, 2016

Study information

Verified date June 2021
Source University of Florida
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study intends to evaluate dynamic respiratory motor performance as a valuable measure of pulmonary function in adults with late-onset Pompe disease. The investigators will adopt a strategy that includes comprehensive evaluations of respiratory volume, flow, and timing parameters during resting and loaded breathing. These evaluations will then be associated to the standard clinical measure of maximal inspiratory pressure, the static inspiratory muscle function, as well as magnetic resonance imaging of thoracic expansion and diaphragmatic descent at rest and with exertion. Outcomes in participants with late-onset Pompe disease will be contrasted to the function of age- and gender-matched control subjects. This approach will enable the investigators to evaluate the relationship between dynamic diaphragmatic function and respiratory motor function.


Description:

The following tests will be completed over a two-day period: Respiratory pressure tests, breathing test, magnetic resonance imaging and magnetic resonance spectroscopy (MRI and MRS).


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date October 19, 2016
Est. primary completion date October 19, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 60 Years
Eligibility Inclusion Criteria: - Confirmed diagnosis of Pompe disease OR - Be an age and gender-matched unaffected control subject Exclusion Criteria: - Pre-existing obstructive lung disease or asthma - Forced vital capacity (FVC) <30% or >80% of age/gender predicted values - Inability to travel to the study site - Requirement for positive pressure ventilator support when awake and upright - Participation in longitudinal studies that may independently alter lung function - Presence of any other chronic medical condition that, in the opinion of the investigator, would make the subject unsuitable for the study

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Thoracic MRI
Imaging of the diaphragm will be completed during resting breathing, and then during a maximal voluntary ventilation maneuver.
Spirometry
Upright forced vital capacity (FVC)
Inspiratory Load Compensation
A spring-loaded pressure device will resist inspiration. The patient must generate the threshold inspiratory pressure to receive airflow. The changes in breathing timing, flow and volume will be recorded.
Maximal Inspiratory Pressure
Measure the maximal airflow on inhalation
Resting Breathing Pattern
The breathing pattern will be assessed when the subject is seated and in a relaxed state.
Respiratory Muscle Endurance Test
Evaluates the time limit that a participant can maintain ventilation while breathing with a submaximal inspiratory threshold load.

Locations

Country Name City State
United States University of Florida Gainesville Florida

Sponsors (2)

Lead Sponsor Collaborator
University of Florida BioMarin Pharmaceutical

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Inspiratory load compensation Peak inspiratory flow, inspiratory volume, and duty cycle of loaded breaths will be measured Day 1
Primary Respiratory muscle endurance task Time and load associated with endurance task failure will be measured. Day 2
Primary Inspiratory load Compensation Peak inspiratory flow, inspiratory volume, and duty cycle of loaded breaths will be measured Day 2
Secondary Thoracic MRI Chest wall and diaphragmatic motions will be measured in three planes with dynamic magnetic resonance imaging (MRI). The change in diaphragm excursion between full inspiration and full expiration will be measured in the frontal plane, and change in the area of the right and left sides of the chest cavity will be measured in the sagittal plane. Diaphragm and chest excursion will be recorded dynamically during 30-second periods of resting breathing and deep breathing. Day 1
See also
  Status Clinical Trial Phase
Completed NCT01942590 - Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy Phase 1/Phase 2
Not yet recruiting NCT01409486 - Screening for Early Detection and Prevention of Pompe Disease in Israel Using Tandem Mass Spectrometry N/A
Completed NCT00976352 - Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease Phase 1/Phase 2
Recruiting NCT01665326 - Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
Completed NCT01758354 - Newborn Screening Assay of Pompe's Disease N/A
Recruiting NCT00231400 - Pompe Disease Registry Protocol
Recruiting NCT04476550 - Clinical Specimen Collection From Pompe Disease Patients
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT01380743 - Drug-drug Interaction Study Phase 2
Recruiting NCT05734521 - Avalglucosidase Alfa Pregnancy Study
Completed NCT02742298 - Pompe Disease QMUS and EIM N/A
Terminated NCT02185651 - A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction Phase 1
Completed NCT02654886 - Safety and Effectiveness of Resistance Exercise Training in Patients With Pompe Disease. N/A
Completed NCT02405598 - Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease Phase 4
Completed NCT00701129 - An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease Phase 4
Completed NCT01451879 - Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies N/A
Completed NCT02240407 - Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease Phase 1
Completed NCT05073783 - A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care Setting
Active, not recruiting NCT04093349 - A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE) Phase 1/Phase 2
Completed NCT02363153 - Diet and Exercise in Pompe Disease N/A